Consolidated net sales for the first quarter increased year over year to 17,242 million yen, operating loss of 68 million yen, ordinary loss of 79 million yen, and net loss attributable to owners of the parent of 36 million yen. Although the pharmaceutical dispensing segment contributed to higher sales, overall profitability deteriorated due to higher cost rates. The full-year outlook is currently unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2796","jir_company_name":"Pharmalize Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2796-20260917-01.pdf","jir_short_summary":"Consolidated net sales for the first quarter increased year over year to 17,242 million yen, operating loss of 68 million yen, ordinary loss of 79 million yen, and net loss attributable to owners of the parent of 36 million yen. Although the pharmaceutical dispensing segment contributed to higher sales, overall profitability deteriorated due to higher cost rates. The full-year outlook is currently unchanged.","jir_summary":"### Overview of results\nIn the first quarter of this term, sales increased year over year, but operating income, ordinary income, and net income declined into loss due to higher cost ratios driven by the dispensing pharmacy business and the impact of revisions to dispensing fees and drug prices. By segment, dispensing pharmacies contributed to sales growth, but profitability did not improve overall. The group will continue to solidify the medium-term plan \u201cMake a Leap 2027,\u201d focusing on strengthening home and facility dispensing and advancing M&A integration processes.\n\n### Outlook and impact on investors\nThe full-year forecast remains unchanged (May period 9th year), but there is a possibility that cost ratio increases and revisions to drug prices and dispensing fees will continue to affect results. In the long term, revenue growth and profit improvements are targeted through contributions from new stores and the advancement of post-M&A integration. Investors should monitor the profitability of the dispensing pharmacy business and the status of home and facility dispensing opportunities.","jir_financial_highlights":"Net sales: 17,242 (YoY 2.9% increase)\nOperating income: 68 (YoY \u25b354.8%)\nOrdinary income: 79 (YoY \u25b331.3%)\nNet income attributable to owners of the parent: -36 (YoY previous period \u25b318)","jir_category":"","jir_hashtags":"#PharmalizeHoldings, #FinancialResults, #DispensingPharmacy, #MediumTermPlanMake a Leap 2027","jir_key_figures":"Net sales: 17,242 million yen (YoY +2.9%)\nOperating income: 68 million yen (YoY \u25b354.8%)\nNet income attributable to owners of the parent: \u25b336 million yen (YoY \u25b318)","jir_meta_title":"Pharmalize Holdings - May Term Year 9 First Quarter Financial Summary: Revenue Up but Loss Widens","jir_meta_description":"Key points from Pharmalize HD's first quarter of Year 9 May term: net sales 17,242 million yen, up 2.9% YoY; operating loss 68 million yen; net loss. Segments show dispensing pharmacies contributing, but high cost ratios are a challenge.","jir_og_title":"Pharmalize Holdings \u2013 Revenue Increase in Q1 but Losses; Advancing Medium-Term Plan","jir_og_description":"In the first quarter, sales rose but the company incurred losses. With a focus on dispensing pharmacies and strengthening home and facility dispensing under its medium-term plan, attention is on future recovery.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\/6\\\",\\\"2024\/9\\\",\\\"2024\/12\\\",\\\"2025\/3\\\",\\\"2025\/6\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[0,0,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024\/6\\\",\\\"2024\/9\\\",\\\"2024\/12\\\",\\\"2025\/3\\\",\\\"2025\/6\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[0,0,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Dispensing Pharmacy\\\",\\\"Retail\\\",\\\"Medical Materials Storage\/Management\\\",\\\"Medical Mall Management\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[0,0,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Revenue\\\",\\\"Operating Income\\\",\\\"Ordinary Income\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Rate\\\",\\\"data\\\":[0,0,0,0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":59671,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-114954","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n